# A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus

> **NCT04935801** · PHASE1 · COMPLETED · sponsor: **Gylden Pharma Ltd** · enrollment: 26 (actual)

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** LD vehicle-GNP
- **BIOLOGICAL:** LD PepGNP-Dengue
- **BIOLOGICAL:** HD vehicle-GNP
- **BIOLOGICAL:** HD PepGNP-Dengue

## Key facts

- **NCT ID:** NCT04935801
- **Lead sponsor:** Gylden Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-02
- **Primary completion:** 2022-03-11
- **Final completion:** 2022-09-15
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2022-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04935801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04935801, "A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04935801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*